Regeneron Pharmaceuticals
REGN
550 hedge funds and large institutions have $26.2B invested in Regeneron Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 69 funds opening new positions, 192 increasing their positions, 224 reducing their positions, and 92 closing their positions.
5% less funds holding
Funds holding: 577 → 550 (-27)
14% less repeat investments, than reductions
Existing positions increased: 192 | Existing positions reduced: 224
15% less call options, than puts
Call options by funds: $493M | Put options by funds: $583M
25% less first-time investments, than exits
New positions opened: 69 | Existing positions closed: 92
34% less capital invested
Capital invested by funds: $39.7B → $26.2B (-$13.5B)
52% less funds holding in top 10
Funds holding in top 10: 27 → 13 (-14)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$988M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$588M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$86.6M |
| 4 |
Two Sigma Advisers
New York
|
+$61.3M |
| 5 |
SGA
Sustainable Growth Advisers
Stamford,
Connecticut
|
+$54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$490M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$296M |
| 3 |
Winslow Capital Management
Minneapolis,
Minnesota
|
-$151M |
| 4 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$145M |
| 5 |
Sands Capital Management
Arlington,
Virginia
|
-$128M |
REGN Hedge Fund Activity: Q1 2016 in Review
550 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q1 2016, worth a combined $26.2B — down 34% from $39.7B a quarter earlier.
Sellers outnumbered buyers: 92 funds closed out of REGN and 69 opened new positions — a net loss of 23 holders — while 224 trimmed existing stakes and 192 added.
The largest buyer was Fidelity Investments, adding an estimated $988M. The largest seller was JP Morgan Chase, cutting an estimated $490M.
- 550 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q1 2016, down from 577 in Q4 2015.
- Funds reported $26.2B of Regeneron Pharmaceuticals stock for Q1 2016, down 34% quarter-over-quarter.
- 69 funds opened new Regeneron Pharmaceuticals positions in Q1 2016 and 92 closed out, a net change of -23 holders.
- The largest Regeneron Pharmaceuticals buyer in Q1 2016 was Fidelity Investments, an estimated $988M added.
- The largest Regeneron Pharmaceuticals seller in Q1 2016 was JP Morgan Chase, an estimated $490M sold.
Based on aggregated 13F filings for Q1 2016.